The study found that mutations were detected in the CSF ctDNA of 20 (95.2%) patients, with a detection rate of epidermal growth factor receptor (EGFR) mutations of 57.1% in CSF ctDNA versus only 23.8% in peripheral blood ctDNA and plasma circulating tumor cells (CTCs). This evidence concerns the gene EGFR and neoplasm.